Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm

Fondation Ophtalmologique Adolphe de Rothschild100 enrolled

Overview

Part of interventional neuroradiology procedures for the treatment of selected cerebral aneurysms are now based on stenting. To reduce thromboembolic events, dual antiplatelet therapy (APT) combining aspirin and clopidogrel is proposed with close monitoring, since 1/3 of the patients are low responders due to variation of the biological response to clopidogrel . Ticagrelor is used by few teams but has never been evaluated in a randomized controlled trial. It could be an option for APT due to more reproducible response with less interindividual variability and reduced monitoring. The aim of this study is to demonstrate the interest of ticagrelor for the dual APT for platelet inhibition, in patients undergoing neurovascular stenting for cerebral aneurysm.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Cerebral Aneurysm

Interventions

clopidogrel: efficacy and safety in cerebral aneurysm stenting

TicagrelorDRUG

ticagrelor:efficacy and safety in cerebral aneurysm stenting

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * unruptured cerebral aneurysm * elective endovascular treatment * stenting required * dual antiplatelet therapy required Exclusion Criteria: -none

Locations (1)

Fondation Ophtalmologique Adolphe de Rothschild

Paris, France

Outcomes

Primary Outcomes

proportion of patients requiring at least one change of drug or dose adjustment to achieve platlet functional inhibition

Time frame: 4 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.